VEII yields 400000.00% · ABBV yields 3.06%● Live data
📍 VEII pulled ahead of the other in Year 1
Combined, VEII + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VEII + ABBV for your $10,000?
Value Exchange International, Inc. provides customer-centric technology solutions to the retail industries in the People's Republic of China, Hong Kong, Malaysia, and the Philippines. The company offers credit and debit card processing services to multinational retailers. It also provides systems maintenance and related services, including software patches and software code revisions; installing, testing, and implementing of software; training of customer personnel for the use of software; and technical support for software systems. In addition, the company offers system installation and implementation services comprising project planning, system analysis and design, hardware and consumables selection advice and sales, and system hardware maintenance services; and systems development and integration services. Further, it engages in the software development; trading and servicing of computer hardware and software; IT service call-center activities; and marketing, sale, and maintenance of point of sale (POS) software under the edgePOS brand, as well as sale of third party POS software programs. The company was formerly known as Sino Payments, Inc. and changed its name to Value Exchange International, Inc. in December 2017. Value Exchange International, Inc. was incorporated in 2007 and is based in Sha Tin, Hong Kong.
Full VEII Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.